PT3488443T - Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada - Google Patents

Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada

Info

Publication number
PT3488443T
PT3488443T PT177433117T PT17743311T PT3488443T PT 3488443 T PT3488443 T PT 3488443T PT 177433117 T PT177433117 T PT 177433117T PT 17743311 T PT17743311 T PT 17743311T PT 3488443 T PT3488443 T PT 3488443T
Authority
PT
Portugal
Prior art keywords
therapy
disease
specific targets
enhanced efficacy
selecting neoepitopes
Prior art date
Application number
PT177433117T
Other languages
English (en)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of PT3488443T publication Critical patent/PT3488443T/pt

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10Ploidy or copy number detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PT177433117T 2016-07-20 2017-07-19 Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada PT3488443T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016067348 2016-07-20

Publications (1)

Publication Number Publication Date
PT3488443T true PT3488443T (pt) 2021-09-24

Family

ID=59399416

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177433117T PT3488443T (pt) 2016-07-20 2017-07-19 Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada

Country Status (22)

Country Link
US (1) US20190189241A1 (pt)
EP (2) EP3967324A1 (pt)
JP (2) JP7171543B2 (pt)
KR (2) KR102516166B1 (pt)
CN (2) CN109477149A (pt)
AU (1) AU2017299162A1 (pt)
BR (1) BR112018077122A8 (pt)
CA (1) CA3031003A1 (pt)
CY (1) CY1124551T1 (pt)
DK (1) DK3488443T3 (pt)
ES (1) ES2890424T3 (pt)
HR (1) HRP20211443T1 (pt)
HU (1) HUE056660T2 (pt)
IL (2) IL264203B1 (pt)
LT (1) LT3488443T (pt)
MX (4) MX2019000733A (pt)
PL (1) PL3488443T3 (pt)
PT (1) PT3488443T (pt)
RS (1) RS62390B1 (pt)
SG (2) SG10201912678QA (pt)
SI (1) SI3488443T1 (pt)
WO (1) WO2018015433A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN111433355B (zh) * 2017-08-10 2024-03-29 古德T细胞有限公司 用于癌症治疗的t细胞的活化方法
CN111213209A (zh) * 2017-10-12 2020-05-29 南托米克斯有限责任公司 根据生物体液的评估用癌症评分和反应预测
CN109294983A (zh) * 2018-09-30 2019-02-01 北京鼎成肽源生物技术有限公司 一种lff2细胞
CN111402954B (zh) * 2019-01-02 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种辨识与预测空间辐射损伤防护药靶相关人类基因的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US20090191556A1 (en) 2006-04-12 2009-07-30 Medical Research Council Method
EP2198292A4 (en) 2007-08-21 2010-09-08 Univ Washington BETTER DIAGNOSIS OF ALZHEIMER'S DISEASE
MX2010002556A (es) 2007-09-07 2010-08-02 Fluidigm Corp Metodos y sistemas para determinar la variacion del numero de copia.
EP3699266A1 (en) * 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
WO2012159754A2 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
AU2012335073B2 (en) * 2011-11-11 2017-08-17 Fred Hutchinson Cancer Center Cyclin A1-targeted T-cell immunotherapy for cancer
US9569586B2 (en) * 2012-02-13 2017-02-14 Albert Rubben Algorithm for modification of somatic cancer evolution
SG11201406250SA (en) 2012-04-05 2014-11-27 Bgi Genomics Co Ltd Method and system for detecting copy number variation
ES2729759T3 (es) * 2012-07-12 2019-11-06 Persimmune Inc Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas
EP2877594B1 (en) 2012-07-20 2019-12-04 Verinata Health, Inc. Detecting and classifying copy number variation in a fetal genome
CN105359151B (zh) 2013-03-06 2019-04-05 生命科技股份有限公司 用于确定拷贝数变异的系统和方法
KR102341899B1 (ko) * 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
US20150331992A1 (en) * 2014-05-15 2015-11-19 Ramot At Tel-Aviv University Ltd. Cancer prognosis and therapy based on syntheic lethality
CN108700592B (zh) * 2015-10-12 2021-08-24 南托米克斯有限责任公司 新表位的迭代发现及其适应性免疫疗法和方法
EP3389630B1 (en) * 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy

Also Published As

Publication number Publication date
ES2890424T3 (es) 2022-01-19
KR102516166B1 (ko) 2023-03-31
MX2023009369A (es) 2023-08-16
WO2018015433A3 (en) 2018-03-01
DK3488443T3 (da) 2021-09-27
SI3488443T1 (sl) 2021-11-30
IL264203A (en) 2019-02-28
MX2023009371A (es) 2023-08-16
HRP20211443T1 (hr) 2021-12-24
CN109477149A (zh) 2019-03-15
EP3488443B1 (en) 2021-08-18
US20190189241A1 (en) 2019-06-20
PL3488443T3 (pl) 2021-12-20
AU2017299162A1 (en) 2019-02-07
HUE056660T2 (hu) 2022-03-28
JP2023009120A (ja) 2023-01-19
MX2019000733A (es) 2019-05-02
KR20190027832A (ko) 2019-03-15
EP3488443A2 (en) 2019-05-29
JP7171543B2 (ja) 2022-11-15
CN117757931A (zh) 2024-03-26
SG10201912678QA (en) 2020-02-27
WO2018015433A2 (en) 2018-01-25
JP2019524106A (ja) 2019-09-05
MX2023009370A (es) 2023-08-16
CY1124551T1 (el) 2022-07-22
BR112018077122A8 (pt) 2023-01-31
EP3488443B8 (en) 2021-09-29
LT3488443T (lt) 2021-10-25
IL264203B1 (en) 2024-04-01
RS62390B1 (sr) 2021-10-29
KR20230019223A (ko) 2023-02-07
IL311369A (en) 2024-05-01
SG11201900132QA (en) 2019-02-27
BR112018077122A2 (pt) 2019-04-30
EP3967324A1 (en) 2022-03-16
CA3031003A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
IL255217B (en) Cancer neo-epitopes
IL254705B (en) Combined treatment for cancer
IL259017A (en) Cancer cure is intended
ZA201702382B (en) Combination therapy for cancer
HUE064857T2 (hu) Kombinációs terápia a rák ellen
HK1231381A1 (zh) 癌症組合療法
IL264203A (en) Selection of neoepitopes as disease-specific targets for therapy with increased efficacy
IL246761A0 (en) Combined cancer treatment
EP3256115A4 (en) COMBINATION CANCER THERAPY
GB201519734D0 (en) Cancer therapy
HK1254687A1 (zh) 用於癌症的聯合療法
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201511609D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy